Adjuvant treatment with pegylated interferon alpha-2a versus low-dose interferon alpha-2a in patients with high-risk melanoma: a randomized phase III DeCOG trial(aEuro)

Eigentler, T. K.; Gutzmer, R.; Hauschild, A.; Heinzerling, L.; Schadendorf, D.; Nashan, D.; Kiecker, F.; Becker, J.; Moll, I.; Richtig, E.; Pehamberger, H.; Kaufmann, R.; Vogt, T.; Berking, C.; Praxmarer, M.; Garbe, C.; Hölzle, E.; Pönitzsch, I.; Sunderkötter, C.; Pföhler, C.

dc.contributor.author	Eigentler, Thomas
dc.contributor.author	Garbe, Claus
dc.date.accessioned	2019-01-22T08:18:32Z
dc.date.available	2019-01-22T08:18:32Z
dc.date.issued	2016
dc.identifier.issn	1569-8041
dc.identifier.uri	http://hdl.handle.net/10900/85831
dc.language.iso	en	de_DE
dc.publisher	Oxford Univ Press	de_DE
dc.relation.uri	http://dx.doi.org/10.1093/annonc/mdw225	de_DE
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject.ddc	610	de_DE
dc.title	Adjuvant treatment with pegylated interferon alpha-2a versus low-dose interferon alpha-2a in patients with high-risk melanoma: a randomized phase III DeCOG trial(aEuro)	de_DE
dc.type	Article	de_DE
utue.quellen.id	20180405102126_01701
utue.publikation.seiten	1625-1632	de_DE
utue.personen.roh	Eigentler, T. K.
utue.personen.roh	Gutzmer, R.
utue.personen.roh	Hauschild, A.
utue.personen.roh	Heinzerling, L.
utue.personen.roh	Schadendorf, D.
utue.personen.roh	Nashan, D.
utue.personen.roh	Kiecker, F.
utue.personen.roh	Becker, J.
utue.personen.roh	Moll, I.
utue.personen.roh	Richtig, E.
utue.personen.roh	Pehamberger, H.
utue.personen.roh	Kaufmann, R.
utue.personen.roh	Vogt, T.
utue.personen.roh	Berking, C.
utue.personen.roh	Praxmarer, M.
utue.personen.roh	Garbe, C.
utue.personen.roh	Hölzle, E.
utue.personen.roh	Pönitzsch, I.
utue.personen.roh	Sunderkötter, C.
utue.personen.roh	Pföhler, C.
dcterms.isPartOf.ZSTitelID	Annals of Oncology	de_DE
dcterms.isPartOf.ZS-Issue	8	de_DE
dcterms.isPartOf.ZS-Volume	27	de_DE
utue.fakultaet	04 Medizinische Fakultät	de_DE